Riskpilot← Back to searchSign inGet full accessNaiRåby med AB
ABActiveOrg 5569053001Tegvägen 1General medical practice activities · NACE 8621Est. 20120 employees
Revenue 2024
SEK 158K
-61% vs 2023
EBITDA margin
17.2%
-90% vs 2023
Equity ratio
53.2%
Financial strength
Net profit 2024
SEK 26K
-88% vs 2023
| Revenue | SEK 158K | -61% |
| EBITDA | SEK 27K | -90% |
| Net profit | SEK 26K | -88% |
| Total assets | SEK 194K | -68% |
| Equity | SEK 103K | -63% |
| Employees | 0 | — |
Legal name
NaiRåby med AB
Org number
5569053001
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
28 september 2012
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Läkartjänster, medicinska konsultationer samt ödemarks- och expeditionsmedicin samt därmed förenlig verksamhet.
Address
Tegvägen 1
Email
johan_linders@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 307 | 405 | 158 |
| Staff expenses | — | — | −10 | −100 | −87 |
| EBITDA | −15 | −3 | 240 | 261 | 27 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −15 | −3 | 240 | 261 | 27 |
| Net financials | — | — | 0 | 2 | 6 |
| Profit before tax | −15 | −3 | 240 | 263 | 33 |
| Tax | −0 | −0 | −36 | −55 | −8 |
| Net profit | −15 | −3 | 204 | 208 | 26 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 30 | 30 | 355 | 610 | 194 |
| Equity | 29 | 26 | 230 | 277 | 103 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 1 | 4 | 126 | 332 | 91 |
| Total debt | 1 | 4 | 126 | 332 | 91 |
EBITDA margin
17.2%
This company
15.8%
Market median
+9% vs market
20202024
Equity ratio
53.2%
This company
38.2%
Market median
+39% vs market
20202024
Return on equity
25.0%
This company
18.4%
Market median
+36% vs market
20202024
Net profit margin
16.3%
This company
8.1%
Market median
+101% vs market
20202024
Asset turnover
0.81×
This company
1.12×
Market median
+28% vs market
20202024
Debt / equity
0.88×
This company
0.62×
Market median
+42% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LJ Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NaiRåby med AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Johan Fredrik Linders | Chief Executive Officer | 0 companies |
| Maria Lovisa Axelsson | Deputy Board Member | 0 companies |